Subsartorial Nerve Block and Femoral Nerve Block in Total Knee Arthroplasty
Launched by LUZERNER KANTONSSPITAL · Oct 3, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two different types of nerve blocks used during total knee replacement surgery, which is done to relieve joint pain and improve mobility. The study aims to find out if one nerve block, called the Subsartorial Saphenous Nerve Block (SSNB), is better than the traditional Femoral Nerve Block (FNB) in helping patients regain strength and function in their legs after surgery. Participants will be randomly assigned to receive one of these two nerve blocks and researchers will compare their recovery outcomes, including muscle strength, pain control, and overall satisfaction with the surgery.
To participate in this trial, individuals must be over 18 years old and scheduled for their first total knee replacement, with a body mass index (BMI) of 35 or less. Participants will receive detailed information about the study before giving their consent. During the trial, patients can expect to be monitored for their recovery progress, including how well they move around and manage pain. It's important to note that certain health conditions or other factors may exclude someone from joining the study. Overall, this research aims to improve recovery options for future knee surgery patients.
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • age \> 18yrs
- • primary TKA
- • BMI 35kg/m2 or less
- • able to give informed consent as documented by signature
- • clinical history without any contraindications for the planned intervention
- Exclusion criteria:
- • age \< 18 years
- • revision-TKA
- • BMI \>35kg/m2
- • absent contact information
- • inability or contraindications to undergo the investigated intervention (TKA, FNB, SSNB), - clinically significant concomitant diseases
- • pregnancy
- • inability to follow the procedures and follow-up procedures of the study (e.g. due to language problems, psychological disorders, dementia, living abroad, etc.
- • withdrawal from the study
About Luzerner Kantonsspital
Luzerner Kantonsspital (LUKS) is a leading academic hospital located in Lucerne, Switzerland, dedicated to providing high-quality healthcare and advancing medical research. As a prominent clinical trial sponsor, LUKS is committed to fostering innovation in medical treatments and therapies through rigorous clinical studies. The institution emphasizes collaboration with multidisciplinary teams of healthcare professionals, researchers, and academic partners to ensure that its trials adhere to the highest ethical standards and regulatory requirements. With a focus on improving patient outcomes, LUKS leverages its state-of-the-art facilities and expertise to contribute significantly to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Luzern, , Switzerland
Patients applied
Trial Officials
Judith Bering, Dr. med.
Principal Investigator
Luzerner Kantonsspital Luzern
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported